Dihydroergocristine
Dihydroergocristine Uses, Dosage, Side Effects, Food Interaction and all others data.
Dihydroergocristine is part of the ergoloid mixture products. It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline. To know more about ergoloid mixtures, please visit Ergoloid mesylate.
Dihydroergocristine has been shown to present effect on memory and cognition. This activity in the brain is been reported by an increase in glutathione in age-related brain states. The reported effect on serotonin and adrenergic receptors has also been correlated to an inhibition of platelet aggregation. It has also been reported that individuals exposed to dihydroergocristine may present an amphoteric vasoregulating activity either hypotensive in hypertensive individuals or hypertensive in hypotensive individuals. This action is performed by promoting a dilating action in the contracted arteries and a tonic action in the dilated arteries and arterioles. The vasoregulating effect causes an increase in cerebral blood flow and oxygen consumption by the brain, which correlates with the brain protective function of dihydroergocristine. In Alzheimer studies, dihydroergocristine reduced the amyloid-beta levels in different cell types. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.
| Trade Name | Dihydroergocristine |
| Generic | Dihydroergocristine |
| Dihydroergocristine Other Names | 9,10-dihydroergocristine, DHEC |
| Type | |
| Formula | C35H41N5O5 |
| Weight | Average: 611.743 Monoisotopic: 611.31076944 |
| Protein binding | Dihydroergocristine can be found in a bound state to plasma proteins in a proportion of even 68% of the administered dose. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate. |
| Groups | Approved, Experimental |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Dihydroergocristine is an ergot alkaloid used to delay progressive mental decline in conditions like Alzheimer's.
Dihydroergocristine is used in some countries such as Brasil as a single agent for the treatment of cerebral and peripheric vascular events. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.
Dihydroergocristine is also used to associated treatment for these conditions: Cerebrovascular Diseases, Cognitive Function, Reduction of Blood Flow, Vascular Diseases of the Extremities, Vascular Disorders, No primary neurologial disease, idiopathic decreased mental activity
How Dihydroergocristine works
Dihydroergocristine mechanism of action seems to be related to a noncompetitive antagonistic activity in the serotonin receptors as well as a double partial agonist/antagonist activity in dopaminergic and adrenergic receptors. In Alzheimer studies, dihydroergocristine act as a direct inhibitor of γ-secretase.
Toxicity
Studies related to acute and chronic toxicity as well as teratogenesis and fertility has proven that dihydroergocristine is a non-toxic and very well tolerated drug. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.
Food Interaction
No interactions found.Volume of Distribution
Dihydroergocristine presents a large volume of distribution of 52 l/kg. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.
Elimination Route
Dihydroergocristine presents an absorption in the digestive tract of about 25% of the administered dose. When dihydroergocristine was orally administered in humans and the peak plasma concentration of 0.28 mcg/l was achieved after 0.46 hours. In the same report, the AUC was reported to be 0.39 mcg/l.h. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.
Half Life
The half-life of dihydroergocristine has only been studied as part of the therapeutic mixture, please refer to Ergoloid mesylate.
Clearance
Dihydroergocristine presents a high systemic clearance rate of 2.65 l/h.hg. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.
Elimination Route
The most important elimination route of dihydroergocristine is in via the bile and it accounts for over 85% of the eliminated dose. Urine elimination accounts only for 5% of the administered dose. To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit Ergoloid mesylate.
Innovators Monograph
You find simplified version here Dihydroergocristine
